Tenax Therapeutics' stock dropped about 84% after its Phase 3 LEVEL trial for TNX-103 failed to meet both primary and key secondary endpoints in treating PH-HFpEF. The drug showed no significant improvement over placebo in walking distance and symptom scores. Despite some exploratory positive signals, the main trial results were disappointing, impacting the company's lead program. Legal firm Levi & Korsinsky is investigating potential securities violations related to the disclosure of trial risks, encouraging affected investors to seek recovery.
Telsey Advisory Group raised Abercrombie & Fitch's price target from $115 to $118, implying an 11.35% upside from the current share price of around $106. Meanwhile, Raymond James downgraded the stock from "Outperform" to "Market Perform," signaling e...
Barclays maintained an "Underweight" rating on Target's stock but raised its price target from $115 to $140, even though Target's shares trade above $161. This cautious stance reflects concerns that Target may underperform its peers despite a strong ...
Heng Chen Seng, a director at Sea Limited, sold 20,000 shares valued at $2.4 million. This insider sale may indicate personal portfolio adjustments but does not necessarily reflect company performance. Investors should monitor further insider activit...
Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive l...
Full Truck Alliance reported a strong second quarter with earnings per share of $0.20, beating analyst expectations by 5.26%. The company saw a 4.4% increase in total net revenues to $498.4 million, driven by a 33.1% rise in transaction service reven...
